Li Xing, Lin Jiami, Zhou Hongxia, Lv Hai-Feng, Yang Lili, Jiang Zhou
Department of Pharmacy, Qiantang Campus, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310018, China.
Department of Nursing, Qiantang Campus, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310018, China.
Indian J Pediatr. 2025 Jan 8. doi: 10.1007/s12098-024-05394-6.
To assess the effects of ω-3 long-chain polyunsaturated fatty acid (LCPUFA)-enriched lipid emulsions (SMOFlipid) vs. traditional soybean oil-based lipid emulsions (Intralipid) on the occurrence and severity of retinopathy of prematurity (ROP) in infants with very low birth weight (VLBW).
In this retrospective cohort study, 301 VLBW infants who received either SMOFlipid or Intralipid for a minimum of 14 d were included. The main outcome measured was the frequency and severity of ROP, with secondary outcomes covering other complications associated with preterm birth.
Of the infants studied, 180 were administered SMOFlipid, while 121 received Intralipid. The incidence of ROP was notably lower in the SMOFlipid group (32.8% vs. 45.5%; RR 0.59; 95% CI 0.36-0.94; P = 0.026). Additionally, the occurrence of severe ROP was reduced by 66.06% in infants given SMOFlipid (5.6% vs. 16.5%; RR 0.30; 95% CI 0.13-0.66; P = 0.002). Multivariate logistic regression suggested that using SMOFlipid was linked to a reduced risk of both ROP (OR 0.44; 95% CI 0.24-0.82; P = 0.010) and severe ROP (OR 0.09; 95% CI 0.03-0.30; P < 0.001). There were no considerable differences noted in other complications associated with preterm birth between the two groups.
Compared to Intralipid, SMOFlipid treatment reduced both the risk and severity of ROP. Parenteral supplementation with fish oil-containing emulsions might offer a novel approach to lowering the incidence and severity of ROP in VLBW infants.
评估富含ω-3长链多不饱和脂肪酸（LCPUFA）的脂质乳剂（SMOFlipid）与传统大豆油基脂质乳剂（英脱利匹特）对极低出生体重（VLBW）婴儿早产儿视网膜病变（ROP）发生情况及严重程度的影响。
在这项回顾性队列研究中，纳入了301例接受SMOFlipid或英脱利匹特治疗至少14天的VLBW婴儿。主要测量结果是ROP的频率和严重程度，次要结果包括与早产相关的其他并发症。
在研究的婴儿中，180例接受了SMOFlipid治疗，121例接受了英脱利匹特治疗。SMOFlipid组ROP的发生率显著较低（32.8%对45.5%；相对危险度0.59；95%置信区间0.36 - 0.94；P = 0.026）。此外，接受SMOFlipid治疗的婴儿严重ROP的发生率降低了66.06%（5.6%对16.5%；相对危险度0.30；95%置信区间0.13 - 0.66；P = 0.002）。多因素逻辑回归分析表明，使用SMOFlipid与ROP（比值比0.44；95%置信区间0.24 - 0.82；P = 0.010）和严重ROP（比值比0.09；95%置信区间0.03 - 0.30；P < 0.001）风险降低相关。两组在与早产相关的其他并发症方面未观察到显著差异。
与英脱利匹特相比，SMOFlipid治疗降低了ROP的风险和严重程度。胃肠外补充含鱼油的乳剂可能为降低VLBW婴儿ROP的发生率和严重程度提供一种新方法。
